30th May 2025 17:00
30 May 2025
Solvonis Therapeutics plc
("Solvonis" or the "Company")
Total Voting Rights
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of addiction and mental health disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 5,908,770,690 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 5,908,770,690.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
Enquiries:
Solvonis Therapeutics plc | |
Anthony Tennyson, CEO & Executive Director |
|
| |
Allenby Capital Limited (Financial Adviser and Joint Broker) | +44 (0) 20 3328 5656 |
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance) Guy McDougall (Sales & Corporate Broking) |
|
Singer Capital Markets (Joint Broker) | +44(0) 20 7496 3000 |
Phil Davies |
|
Related Shares:
Solvonis Therap